BioMAP offers insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
The Patent no. 7,908,089, entitled ‘Patient classification,’ relates to BioMAP and its use for the classification of clinical patient tissue specimens according to the physiological status of cells present in the sample.
However, patent no. 7,912,651, entitled, ‘Function homology screening,’ covers key methods of cell selection, culture conditions and screening of biologically active agents utilised by the BioMAP Systems technology.
Asterand CEO Martyn Coombs said their BioMAP technology addresses a major unmet need in drug development for model systems that reflect the complexity of human disease.